Scott is joined by Motley Fool Director of Research Kevin Gandiya to talk about pathology services growth story Australian Clinical Labs (ASX:ACL): What it does, what’s impressive, the risks of an investment in the company, and why he thinks it’s a Buy!
See omnystudio.com/listener for privacy information.
view more